What is the difference between Cosibelimab and common PD-L1 drugs?

Cosibelimab (Cosibelimab) is a new anti-PD-L1 (programmed death ligand1) monoclonal antibody developed by the American biopharmaceutical company Checkpoint Therapeutics. Compared with common PD-L1 inhibitors currently on the market such as atezolizumab (Atezolizumab), durvalumab (Durvalumab ), Cosibelimab not only has a similar immune mechanism, but also shows unique advantages in structural design, antibody type, Fc segment function and market strategy, and has gradually gained attention in the industry.

In terms of mechanism of action, Cosibelimab is the same as other PD-L1 antibodies, by blocking PD-L1Binds with the PD-1 receptor on the surface of T cells to relieve the suppression of the immune system, thereby activating the immune killing of T cells against tumor cells. But the difference is that Cosibelimab retains the function of Fc segment and has antibody-dependent cell-mediated cytotoxicity (ADCC ) ability, which means that in addition to activating T cells, it can also directly induce NK cells to mediate the clearance of tumor cells. This mechanism may enhance its anti-tumor effect in certain tumor types.

CosibelimabEmphasis on the "high cost performance" strategy during the development stage. Compared with other marketed PD-L1 antibodies that have high prices and a saturated market, Checkpoint Therapeutics intends to position Cosibelimab as a more cost-effective alternative drug, especially for developing countries or regional markets with strict medical insurance controls. In addition, it has shown good efficacy and safety in clinical studies, such as in the treatment of metastatic Merkel cell carcinoma (MCC) has demonstrated an objective response rate (ORR) of over 40% and has been granted "Fast Track" and "Orphan Drug" designations by the U.S. FDA.

From the perspective of antibody structure, Cosibelimab adopts a fully humanized IgG1 monoclonal antibody design, which reduces immunogenicity and improves the safety and tolerability of long-term medication. Unlike some PD-L1 antibodies that remove the Fc functional segment, Cosibelimab maintains Retaining Fc activity may bring about more complex immune regulatory effects, which makes it potentially differentially effective in dealing with certain tumors with strong PD-L1 expression or obvious immune evasion.

Reference materials:https://www.drugs.com/